drugset / Trial / NCT06739395
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The main purpose of this study is to explore the feasibility of selecting treatment plans based on genomic variations guided by MTB in patients with advanced refractory solid tumors.
Timeline
- Start
- 2024-11-01
- Primary completion
- 2026-12-31
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | 300 mg | — |
| Subject | Catequentinib | Small molecule | — | Oral |
| Subject | Dabrafenib | Small molecule | 150 mg | Oral |
| Subject | Lenvatinib | Small molecule | 8 mg | — |
| Subject | Lenvatinib | Small molecule | 12 mg | — |
| Subject | Olaparib | Small molecule | 200 mg | — |
| Subject | Palbociclib | Small molecule | 100 mg | Oral |
| Subject | Pazopanib | Small molecule | 400 mg | Oral |
| Subject | Pazopanib | Small molecule | 600 mg | Oral |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |
| Subject | Tucidinostat | Small molecule | 30 mg | — |
| Subject | Vebreltinib | Small molecule | 200 mg | Oral |